0.00Open0.05Pre Close0 Volume127 Open Interest15.00Strike Price0.00Turnover0.00%IV39.40%PremiumApr 25, 2025Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma493.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
Akeso, Summit’s partner, released interim overall survival data for ivonescimab, a PD-1/VEGF bispecific antibody, in a Chinese Phase 3 trial (HARMONi-2) comparing it to Merck’s Keytruda for first-line PD-L1-positive non-small cell lung cancer (NSCLC). The hazard ratio for OS was reported as 0.777 (corrected from an initial 0.784), indicating a 22% reduction in the risk of death compared to Keytruda. However, this result was be...
what's the issue here? can anyone explain?
What's Going On With Summit Therapeutics Stock On Friday? - Summit Therapeutics (NASDAQ:SMMT) - Benzinga
The $Nasdaq Composite Index (.IXIC.US)$ scored the session's largest gains, adding 216.90 points (1.3%) to 17,383.94. Meanwhile, the $S&P 500 Index (.SPX.US)$ added 40.44 ticks...
was this a halt? what happened?
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
04/25/2025 - 11:50 AM
Interim Analysis of HARMONi-2 Shows an Overall Survival Hazard Ratio of 0.777 Favoring Ivonescimab at 39% Data Maturity, Implying a Potential Numerical 22%Reduction in the Risk of Death Compar...
No comment yet